Eli Lilly and Company (NYSE:LLY) Shares Acquired by Scott Capital Advisors LLC

Scott Capital Advisors LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 2.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 738 shares of the company’s stock after buying an additional 17 shares during the period. Scott Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $654,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of LLY. Bragg Financial Advisors Inc increased its position in Eli Lilly and Company by 278.2% during the fourth quarter. Bragg Financial Advisors Inc now owns 7,655 shares of the company’s stock worth $4,462,000 after purchasing an additional 5,631 shares during the last quarter. Barden Capital Management Inc. increased its position in Eli Lilly and Company by 17.0% during the fourth quarter. Barden Capital Management Inc. now owns 3,776 shares of the company’s stock worth $2,047,000 after purchasing an additional 548 shares during the last quarter. Baird Financial Group Inc. increased its position in Eli Lilly and Company by 5.2% during the fourth quarter. Baird Financial Group Inc. now owns 226,653 shares of the company’s stock worth $132,121,000 after purchasing an additional 11,124 shares during the last quarter. Bridgeway Capital Management LLC increased its position in Eli Lilly and Company by 1.2% during the fourth quarter. Bridgeway Capital Management LLC now owns 31,941 shares of the company’s stock worth $18,619,000 after purchasing an additional 365 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in Eli Lilly and Company by 38.6% during the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 417,700 shares of the company’s stock worth $243,486,000 after purchasing an additional 116,300 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Morgan Stanley reiterated an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, September 16th. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $979.29.

Eli Lilly and Company Stock Up 0.2 %

NYSE LLY traded up $1.75 during trading hours on Friday, reaching $912.44. 218,719 shares of the company traded hands, compared to its average volume of 2,999,024. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The stock has a market capitalization of $867.21 billion, a PE ratio of 112.15, a PEG ratio of 2.79 and a beta of 0.42. The company has a 50 day moving average of $908.28 and a two-hundred day moving average of $851.21.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, equities analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.